Search research articles
Contact Us
Filters
Showing results (71-80 of 82) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>
F Montemurro, S Delaloge, C H Barrios, et al.
Experimental Neurology
|
May 8, 2016
FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation
S V Precious, C M Kelly, A E Reddington, et al.
Cell Death and Differentiation
|
January 8, 2011
Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells
O Cordero-Llana, S A Scott, S L Maslen, et al.
Cell Transplantation
|
March 15, 2011
Medical terminations of pregnancy: a viable source of tissue for cell replacement therapy for neurodegenerative disorders
C M Kelly, S V Precious, E M Torres, et al.
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Breast Cancer Research and Treatment
|
April 9, 2021
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland
L M McSorley, M Tharmabala, F Al Rahbi, et al.
Irish Journal of Medical Science
|
April 11, 2025
CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland
W J Mullally, A Hassan, N Keegan, et al.
ESMO Open
|
July 27, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
E Rosenbaum, K Seier, M Bradic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Breast Cancer Research and Treatment
|
October 4, 2024
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
I M Browne, R A McLaughlin, C S Weadick, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 82) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>
F Montemurro, S Delaloge, C H Barrios, et al.
Experimental Neurology
|
May 8, 2016
FoxP1 marks medium spiny neurons from precursors to maturity and is required for their differentiation
S V Precious, C M Kelly, A E Reddington, et al.
Cell Death and Differentiation
|
January 8, 2011
Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells
O Cordero-Llana, S A Scott, S L Maslen, et al.
Cell Transplantation
|
March 15, 2011
Medical terminations of pregnancy: a viable source of tissue for cell replacement therapy for neurodegenerative disorders
C M Kelly, S V Precious, E M Torres, et al.
ESMO Open
|
June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
F Marmé, M Martin, M Untch, et al.
Breast Cancer Research and Treatment
|
April 9, 2021
Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland
L M McSorley, M Tharmabala, F Al Rahbi, et al.
Irish Journal of Medical Science
|
April 11, 2025
CTRIAL-IE (ICORG) 15-34: The impact of the 21 gene breast recurrence score® assay on chemotherapy prescribing in oestrogen receptor positive, lymph node positive early stage breast cancer in Ireland
W J Mullally, A Hassan, N Keegan, et al.
ESMO Open
|
July 27, 2025
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
E Rosenbaum, K Seier, M Bradic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2025
Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B
S Loibl, M Martin, H Bonnefoi, et al.
Breast Cancer Research and Treatment
|
October 4, 2024
Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer
I M Browne, R A McLaughlin, C S Weadick, et al.
Page
of 9